Pharma Update
Strategic pillars of oncology
Precision medicine
Right medicines at the
right patient
inavolisib
INAVO 120 (1L HR+ Pi3Km
BC) data expected 2023
divarasib
Recently published data
in NEJM
Early disease
Novel immunotherapy
Early diagnosis and
treatment increases the
chance for cure
Alecensa
ALINA (adj ALK+ NSCLC)
positive data
giredestrant
Potential to replace ET in
eBC (and mBC)
Need more options for
patients who have
progressed on prior
treatment
Recent/emerging examples
tiragolumab + Tecentriq
Ph Ill in 1L HCC initiated
Tombestomig
(PD1 x LAG3)
00
Rational combinations
Leverage breadth of
oncology portfolio to
explore new
combinations
Polivy + Columvi +R-CHP
Ph Ill trial in 1L DLBCL to
be initiated
Multiple Ph II trials initiated
(e.g. mUC, NSCLC, RCC)
giredestrant + Phesgo
HeredERA (1L HER2+/HR+
BC)
()
New modalities
Invest in potentially
transformative science
AR Degrader
Ph I trial in mCRPC with
FPI in Q2
PROTAB
Recent paper published in
Nature
HCC-Hepatocellular carcinoma; NSCLC-Non-Small Cell Lung Cancer; R-CHP-Rituxan + cyclophosphamide + hydroxydaunorubicin + prednisone; DLBCL-Diffuse large B-cell lymphoma; Pi3K-Phosphoinositide 3-Kinase;
NEJM-New England Journal of Medicine; ET-Endocrine therapy; eBC-Early breast cancer; mBC=Metastatic breast cancer; HR=Hormone receptor;adj-adjuvant; mUC=Metastatic urothelial carcinoma; RCC=Renal cell carcinoma;
HER2-Human epidermal growth factor receptor 2; mCRPC-Metastatic castration-resistant prostate cancer
69
69
RocheView entire presentation